Interim Report - January-March 2024
April 26, 2024 02:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is available on the Company's website. “2024 has...
Amundi: Résultats du premier trimestre 2024
April 26, 2024 00:59 ET
|
Amundi
Amundi: Résultats du premier trimestre 2024 Encours gérés au plus haut historiqueCollecte dynamique de +17 Md€, résultat net1,2 en hausse de +6% T1/T1 Un résultat net en hausse Haut niveau de...
Y-mAbs to Present at 2024 ASCO Annual Meeting
April 25, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Kering : Descriptif du programme de rachat d'actions autorisé par l'Assemblée générale
April 25, 2024 12:50 ET
|
KERING
Kering - Communiqué de presse - Descriptif du programme de rachat d'actions - 25 avril 2024 COMMUNIQUÉ DE PRESSE 25.04.2024 DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONSAUTORISÉ PAR...
Valeo Chiffre d'affaires du 1er trimestre 2024 - Au 1er trimestre, chiffre d’affaires de 5,4 milliards d’euros, en hausse de 2 % à périmètre et taux de change constants
April 25, 2024 12:00 ET
|
Valeo
PARISLe 25 avril 2024 Au 1er trimestre, chiffre d’affaires de 5,4 milliards d’euros, en hausse de 2 % à périmètre et taux de change constants Objectifs 2024 et 2025 réaffirmés Chiffre...
Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
April 25, 2024 09:14 ET
|
Aclarion, Inc.
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system ...
One Stop Systems to Report First Quarter 2024 Financial Results
April 25, 2024 08:31 ET
|
One Stop Systems, Inc.
ESCONDIDO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (“OSS” or the "Company") (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI),...
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
April 25, 2024 08:30 ET
|
Apollomics Inc.
Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion...
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024 07:30 ET
|
XOMA Corporation
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
April 25, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback ...